Open AccessGemcitabine–oxaliplatin (GEMOX) for epithelial ovarian cancer patients resistant to platinum-based chemotherapy
Author(s) -
Mohamed Abdo El-Shebeiny,
Walid Ahmed Almorsy
Publication year - 2016
Publication title -
journal of the egyptian national cancer institute
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.398
H-Index - 22
eISSN - 2589-0409
pISSN - 1110-0362
DOI - 10.1016/j.jnci.2016.04.005
Subject(s) - oxaliplatin , medicine , gemcitabine , ovarian cancer , oncology , chemotherapy , epithelial ovarian cancer , platinum , cancer , colorectal cancer , biochemistry , chemistry , catalysis
Patients with platinum-resistant epithelial ovarian cancer (EOC) experience poor outcome. Currently, no clearly superior management strategy exists for platinum-resistant EOC patients.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom